Therapeutic targeting of the endothelin-A receptor in human ovarian carcinoma: Efficacy of cytotoxic agents is markedly enhanced by co-administration with atrasentan

Laura Rosanò, Francesca Spinella, Valeriana Di Castro, Pier Giorgio Natali, Anna Bagnato

Research output: Contribution to journalArticle

Abstract

The endothelin-1/endothelin-A receptor autocrine pathway is overexpressed in ovarian carcinoma. We explored the efficacy of atrasentan (ABT-627), a small orally active endothelin-A receptor antagonist, in monotherapy and combination therapy on HEY ovarian carcinoma xenografts. Atrasentan (2 mg/kg per 24 hours i.p. for 21 days) induced similar inhibition of tumor growth as paclitaxel (20 mg/kg i.v. three times a day every 4 days) with a reduction of 65% compared to control. The co-administration of atrasentan enhanced the efficacy of cytotoxic agents, such as taxanes or platinum compounds. Administration of atrasentan in combination with paclitaxel caused a strong antitumor effect. Remarkably, four of ten mice bearing HEY xenografts had no histological evidence of tumors. Tumor growth inhibition was accompanied by a significant decrease of molecular effectors involved in angiogenesis and invasion and by enhanced tumor cell apoptosis. Moreover, although cisplatinum as a single agent (5 mg/kg i.p. on day 1) markedly inhibited HEY tumors, atrasentan was very effective in potentiating this effect, with partial or complete tumor regression. The antitumor, anti-angiogenic, and apoptotic activities obtained with atrasentan and the enhanced efficacy of cytotoxic agents provide a rationale for its clinical evaluation in ovarian carcinoma.

Original languageEnglish
JournalJournal of Cardiovascular Pharmacology
Volume44
Issue numberSUPPL. 1
DOIs
Publication statusPublished - Nov 2004

Fingerprint

Endothelin A Receptors
Cytotoxins
Carcinoma
Neoplasms
Paclitaxel
Heterografts
Therapeutics
Platinum Compounds
Taxoids
Endothelin-1
Growth
atrasentan
Apoptosis

Keywords

  • ABT-627
  • Cisplatinum
  • Endothelin-1 (ET-1)
  • Ovarian carcinoma
  • Paclitaxel

ASJC Scopus subject areas

  • Pharmacology
  • Cardiology and Cardiovascular Medicine

Cite this

Therapeutic targeting of the endothelin-A receptor in human ovarian carcinoma : Efficacy of cytotoxic agents is markedly enhanced by co-administration with atrasentan. / Rosanò, Laura; Spinella, Francesca; Di Castro, Valeriana; Natali, Pier Giorgio; Bagnato, Anna.

In: Journal of Cardiovascular Pharmacology, Vol. 44, No. SUPPL. 1, 11.2004.

Research output: Contribution to journalArticle

@article{b98bb1727a544258acf26fc1cb1ff81f,
title = "Therapeutic targeting of the endothelin-A receptor in human ovarian carcinoma: Efficacy of cytotoxic agents is markedly enhanced by co-administration with atrasentan",
abstract = "The endothelin-1/endothelin-A receptor autocrine pathway is overexpressed in ovarian carcinoma. We explored the efficacy of atrasentan (ABT-627), a small orally active endothelin-A receptor antagonist, in monotherapy and combination therapy on HEY ovarian carcinoma xenografts. Atrasentan (2 mg/kg per 24 hours i.p. for 21 days) induced similar inhibition of tumor growth as paclitaxel (20 mg/kg i.v. three times a day every 4 days) with a reduction of 65{\%} compared to control. The co-administration of atrasentan enhanced the efficacy of cytotoxic agents, such as taxanes or platinum compounds. Administration of atrasentan in combination with paclitaxel caused a strong antitumor effect. Remarkably, four of ten mice bearing HEY xenografts had no histological evidence of tumors. Tumor growth inhibition was accompanied by a significant decrease of molecular effectors involved in angiogenesis and invasion and by enhanced tumor cell apoptosis. Moreover, although cisplatinum as a single agent (5 mg/kg i.p. on day 1) markedly inhibited HEY tumors, atrasentan was very effective in potentiating this effect, with partial or complete tumor regression. The antitumor, anti-angiogenic, and apoptotic activities obtained with atrasentan and the enhanced efficacy of cytotoxic agents provide a rationale for its clinical evaluation in ovarian carcinoma.",
keywords = "ABT-627, Cisplatinum, Endothelin-1 (ET-1), Ovarian carcinoma, Paclitaxel",
author = "Laura Rosan{\`o} and Francesca Spinella and {Di Castro}, Valeriana and Natali, {Pier Giorgio} and Anna Bagnato",
year = "2004",
month = "11",
doi = "10.1097/01.fjc.0000166259.96980.6a",
language = "English",
volume = "44",
journal = "Journal of Cardiovascular Pharmacology",
issn = "0160-2446",
publisher = "Lippincott Williams and Wilkins",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Therapeutic targeting of the endothelin-A receptor in human ovarian carcinoma

T2 - Efficacy of cytotoxic agents is markedly enhanced by co-administration with atrasentan

AU - Rosanò, Laura

AU - Spinella, Francesca

AU - Di Castro, Valeriana

AU - Natali, Pier Giorgio

AU - Bagnato, Anna

PY - 2004/11

Y1 - 2004/11

N2 - The endothelin-1/endothelin-A receptor autocrine pathway is overexpressed in ovarian carcinoma. We explored the efficacy of atrasentan (ABT-627), a small orally active endothelin-A receptor antagonist, in monotherapy and combination therapy on HEY ovarian carcinoma xenografts. Atrasentan (2 mg/kg per 24 hours i.p. for 21 days) induced similar inhibition of tumor growth as paclitaxel (20 mg/kg i.v. three times a day every 4 days) with a reduction of 65% compared to control. The co-administration of atrasentan enhanced the efficacy of cytotoxic agents, such as taxanes or platinum compounds. Administration of atrasentan in combination with paclitaxel caused a strong antitumor effect. Remarkably, four of ten mice bearing HEY xenografts had no histological evidence of tumors. Tumor growth inhibition was accompanied by a significant decrease of molecular effectors involved in angiogenesis and invasion and by enhanced tumor cell apoptosis. Moreover, although cisplatinum as a single agent (5 mg/kg i.p. on day 1) markedly inhibited HEY tumors, atrasentan was very effective in potentiating this effect, with partial or complete tumor regression. The antitumor, anti-angiogenic, and apoptotic activities obtained with atrasentan and the enhanced efficacy of cytotoxic agents provide a rationale for its clinical evaluation in ovarian carcinoma.

AB - The endothelin-1/endothelin-A receptor autocrine pathway is overexpressed in ovarian carcinoma. We explored the efficacy of atrasentan (ABT-627), a small orally active endothelin-A receptor antagonist, in monotherapy and combination therapy on HEY ovarian carcinoma xenografts. Atrasentan (2 mg/kg per 24 hours i.p. for 21 days) induced similar inhibition of tumor growth as paclitaxel (20 mg/kg i.v. three times a day every 4 days) with a reduction of 65% compared to control. The co-administration of atrasentan enhanced the efficacy of cytotoxic agents, such as taxanes or platinum compounds. Administration of atrasentan in combination with paclitaxel caused a strong antitumor effect. Remarkably, four of ten mice bearing HEY xenografts had no histological evidence of tumors. Tumor growth inhibition was accompanied by a significant decrease of molecular effectors involved in angiogenesis and invasion and by enhanced tumor cell apoptosis. Moreover, although cisplatinum as a single agent (5 mg/kg i.p. on day 1) markedly inhibited HEY tumors, atrasentan was very effective in potentiating this effect, with partial or complete tumor regression. The antitumor, anti-angiogenic, and apoptotic activities obtained with atrasentan and the enhanced efficacy of cytotoxic agents provide a rationale for its clinical evaluation in ovarian carcinoma.

KW - ABT-627

KW - Cisplatinum

KW - Endothelin-1 (ET-1)

KW - Ovarian carcinoma

KW - Paclitaxel

UR - http://www.scopus.com/inward/record.url?scp=11144337535&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11144337535&partnerID=8YFLogxK

U2 - 10.1097/01.fjc.0000166259.96980.6a

DO - 10.1097/01.fjc.0000166259.96980.6a

M3 - Article

C2 - 15838262

AN - SCOPUS:11144337535

VL - 44

JO - Journal of Cardiovascular Pharmacology

JF - Journal of Cardiovascular Pharmacology

SN - 0160-2446

IS - SUPPL. 1

ER -